TherapeuticsMD reported a net loss of $636 thousand for Q1 2025, a slight improvement compared to the previous year. License revenue increased by 25.8%, primarily driven by changes in sales of licensed products. Total operating expenses decreased due to increased efficiencies as a royalty-based business. The company is also evaluating strategic alternatives.

TherapeuticsMD reported a significant decrease in net loss for the full year 2024, down to $(2.3) million from $(7.7) million in 2023. License revenue increased by 35.3% to $1.8 million, primarily due to changes in sales of licensed products, while total operating expenses decreased by 33.6% to $6.5 million, reflecting the company's transition to a royalty-based business.

TherapeuticsMD, a pharmaceutical royalty company, reported its financial results for the third quarter ended September 30, 2024. The company is primarily collecting royalties from its licensees.

TherapeuticsMD reported financial results for the second quarter ended June 30, 2024, focusing on license and service revenues as a pharmaceutical royalty company.

TherapeuticsMD, Inc. reported financial results for the first quarter ended March 31, 2024, focusing on pharmaceutical royalties collection after transitioning from a women's healthcare company in December 2022.

TherapeuticsMD, a pharmaceutical royalty company, reported full year 2023 financial results and continues to explore strategic alternatives to maximize shareholder value.

TherapeuticsMD reported Q3 2023 financial results, highlighting a net loss from continuing operations of $1.4 million, or $0.13 per share, and license and service revenues of $(0.1) million. The company is focused on cost control and is evaluating strategic alternatives.

TherapeuticsMD reported a net loss from continuing operations of $2.4 million for the second quarter of 2023, with license and service revenues of $0.4 million. The company is transitioning to a royalty-based business and focusing on cost reduction.

TherapeuticsMD reported first quarter 2023 financial results, featuring a net loss from continuing operations of $2.3 million, or $0.24 per share, and license and service revenues of $0.4 million. The company's transition to a royalty-based business model led to decreased operating expenses and a focus on winding down commercial operations.

TherapeuticsMD reported full year 2022 financial results, highlighting a transition to a virtual business model following a transaction with Mayne Pharma. The company repaid its debt, redeemed preferred stock, and eliminated its commercial and manufacturing infrastructure.

TherapeuticsMD reported a decrease in net revenues by $4.5 million compared to the prior year, but reduced operating expenses by $22 million year-over-year. The company's wholesale network is now fully stocked, and operations have stabilized after a cash infusion from Rubric Capital.

TherapeuticsMD reported a solid revenue growth of 24% compared to the prior year period and a decrease of 21% in operating expenses. The FDA approved their supplemental new drug application for ANNOVERA, enhancing their ability to meet product demand. They also repaid $120 million of debt using proceeds from the divestiture of their vitaCare unit.

TherapeuticsMD reported a total net product revenue of $19.3 million for Q1 2022. ANNOVERA TRx reached 8,014, a 27% increase over Q1 2021. The company completed the vitaCare divestiture in five weeks.

TherapeuticsMD announced its Q4 2021 financial results, highlighting a definitive agreement to divest the vitaCare business unit and amended credit terms with Sixth Street. Demand for ANNOVERA continues to grow, and the company is focused on ensuring ample supply and access.

TherapeuticsMD announced key leadership changes, appointing Hugh O’Dowd as CEO, succeeding Robert G. Finizio, effective on or before December 31, 2021. Finizio was appointed Vice Chair of the Board.

TherapeuticsMD reported a 17% increase in total net product revenue compared to Q1 2021, reaching $23 million. Prescription growth was driven by ANNOVERA and IMVEXXY, with improved access to providers and increased telemedicine options. vitaCare signed a new customer, expanding its pipeline.

TherapeuticsMD reported a 60% increase in total net product revenue to $19.6 million for Q1 2021 compared to Q1 2020, driven by growth in ANNOVERA, IMVEXXY and BIJUVA. The company obtained three new ANNOVERA patents and won its appeal for the new low-dose BIJUVA 0.5/100 with the FDA.

TherapeuticsMD announced its Q4 and full-year 2020 financial results, highlighted by a 30% increase in total net product revenue for Q4 compared to Q3, and an 84% increase for the full year compared to 2019. The company also amended its financing agreement, updated net revenue covenants, and plans to pay down $50 million in debt.

TherapeuticsMD reported a strong quarter with record growth across its product portfolio, achieving an 80% increase in total net revenue to $19.3 million compared to 2Q20 and a 250% increase in ANNOVERA net revenue for 3Q20 compared to 2Q20. The company also reduced its 3Q20 cash burn by $22 million compared to 2Q20.

TherapeuticsMD reported a net product revenue of $10.7 million for Q2 2020. The company focused on reducing operating expenses and reorienting the sales force. Net loss for the quarter was $52.0 million, or $0.19 per basic and diluted share.

TherapeuticsMD reported Q1 2020 financial results, with net product revenue of $12.3 million. The company significantly reduced operating expenses and is aiming for EBITDA breakeven in 2021. The launch of ANNOVERA was paused due to the COVID-19 pandemic.

TherapeuticsMD announced Q4 2019 net product revenue of $15.9 million, exceeding the company's financial guidance. Full-year 2019 total net product revenue reached $34.1 million, hitting the top end of the financial guidance. The company launched ANNOVERA and expects full-year 2020 net product revenue of $90 million to $110 million.